Lakewood-Amedex CEO to Present at H.C. Wainwright Conference
Event summary
- Lakewood-Amedex Biotherapeutics CEO Kelvin Cooper, Ph.D., will present virtually at the H.C. Wainwright 28th Annual Global Investment Conference on September 14-16, 2026.
- Dr. Cooper will conduct one-on-one meetings with registered investors and potential partners.
- The company is developing Bisphosphocin® class antimicrobials to combat antibiotic-resistant bacterial strains, including MRSA and VRE.
The big picture
Lakewood-Amedex's participation in the H.C. Wainwright conference underscores the growing emphasis on antimicrobial innovation amid rising antibiotic resistance. The company's focus on fast-acting, broad-spectrum solutions positions it within a critical niche, but success hinges on translating clinical potential into commercial viability. The conference serves as a platform to gauge investor appetite for early-stage biotech plays in this high-stakes therapeutic area.
What we're watching
- Clinical Milestones
- The pace at which Lakewood-Amedex advances its Bisphosphocin® class antimicrobials through clinical trials will determine its near-term valuation.
- Investor Sentiment
- How the company's presentation and one-on-one meetings impact investor interest and potential partnerships.
- Market Differentiation
- Whether Lakewood-Amedex can effectively position its broad-spectrum antimicrobials against competitors in the antibiotic-resistant space.
Related topics